Personalized insight through next-generation sequencing
Improve disease classification and guide therapy decisions
Melanoma accounts for just 1% of skin cancer diagnoses but causes the majority of skin cancer deaths.1 Because of the heterogeneity of melanoma and unique genetic features of the cancer, prognosis and treatment can vary greatly. Accurate classification of an individual’s melanoma is vital to both understanding the illness’s implications on the patient and placing them on the proper treatment path.
Learn more about our full suite of MayoComplete next-generation sequencing panels for hematologic and oncologic conditions.
By the numbers
new melanomas diagnosed in 20221
genetic loci associated with melanoma2
carefully selected genes associated with melanoma included on the MayoComplete melanoma panel
Mayo Clinic Laboratories melanoma testing uses next-generation sequencing to identify variants in 17 genes associated with diagnosis, prognosis, and treatment guidance. Offering increased sensitivity for heightened accuracy, our comprehensive melanoma evaluation includes full exonic sequencing of the genes, as opposed to evaluating only targeted areas. The MayoComplete Melanoma Panel can help to identify difficult tumors or classify known tumors for targeted therapy guidance. In addition, our assay provides information on microsatellite instability (MSI).
When to consider testing
Genes included in MayoComplete Melanoma Panel*
Melanoma panel provides more tumor information
In this test specific episode of the "Answers From the Lab" podcast, Ruifeng (Ray) Guo, M.D., Ph.D., explains how Mayo Clinic Laboratories' comprehensive melanoma panel better informs prognosis and treatment.
Answers, not just results
Because testing is complex and selecting the right assay can be challenging, our team of board-certified geneticists and genetic counselors is available to assist with questions related to testing options and results interpretation.